Publication | Open Access

Pre-therapeutic 124I PET(/CT) dosimetry confirms low average absorbed doses per administered 131I activity to the salivary glands in radioiodine therapy of differentiated thyroid cancer

Radiation TherapyMedicineThyroid DiseaseSalivary GlandsRadiopharmaceutical TherapyRadioiodine TherapyDifferentiated Thyroid CancerOncologyRadiation OncologyNuclear MedicineRadiologyHealth Sciences